EGFR (E746-A750del Specific), Cell Signaling Technology, 2085

We generated a top 1000 list of the most studied and most published proteins and analyzed the literature validation data for the commercially available research antibody tools. EGFR is the third most studied gene on the list. Cell Signaling 2085 was validated in the original peer-reviewed paper from Cell Signaling Technology by Yu et al., 2009, Clinical Cancer Research entitled Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer The authors tested the mutation-specific antibody by Western blot, immunofluorescence, and immunohistochemistry. Clone 6B6/#2085 was screened against six human cancer cell lines with known EGFR genotypes. It detected E746_A750del EGFR in H1650 and HCC827, but not WT EGFR in Kyse450/Kyse70 or the L858R mutant recognized by the other mutation-specific antibody described in the publication. The #2085 antibody was tested on paraffin-embedded NSCLC specimens and compared against independently determined EGFR mutation status by DNA sequencing. Across the two mutation-specific antibodies, the IHC assay achieved 92% sensitivity and 99% specificity relative to sequencing. Yu et al. report that the antibody specifically detected their corresponding mutant EGFR forms by immunofluorescence as well. Dilution is not disclosed in the publication. We rated the Cell Signaling antibody based on the available information and according to the pAbmAbs criteria.